Investigating the inequalities in route to diagnosis amongst patients with diffuse large B-cell or follicular lymphoma in England. by Smith, Matthew J et al.
ARTICLE OPEN
Epidemiology
Investigating the inequalities in route to diagnosis amongst
patients with diffuse large B-cell or follicular lymphoma
in England
Matthew J. Smith 1✉, Miguel Angel Luque Fernandez 1,2, Aurélien Belot 1, Matteo Quartagno3, Audrey Bonaventure4,
Sara Benitez Majano1, Bernard Rachet1 and Edmund Njeru Njagi1
© The Author(s) 2021
INTRODUCTION: Diagnostic delay is associated with lower chances of cancer survival. Underlying comorbidities are known to
affect the timely diagnosis of cancer. Diffuse large B-cell (DLBCL) and follicular lymphomas (FL) are primarily diagnosed amongst
older patients, who are more likely to have comorbidities. Characteristics of clinical commissioning groups (CCG) are also known to
impact diagnostic delay. We assess the association between comorbidities and diagnostic delay amongst patients with DLBCL or FL
in England during 2005–2013.
METHODS: Multivariable generalised linear mixed-effect models were used to assess the main association. Empirical Bayes
estimates of the random effects were used to explore between-cluster variation. The latent normal joint modelling multiple
imputation approach was used to account for partially observed variables.
RESULTS:We included 30,078 and 15,551 patients diagnosed with DLBCL or FL, respectively. Amongst patients from the same CCG,
having multimorbidity was strongly associated with the emergency route to diagnosis (DLBCL: odds ratio 1.56, CI 1.40–1.73; FL:
odds ratio 1.80, CI 1.45–2.23). Amongst DLBCL patients, the diagnostic delay was possibly correlated with CCGs that had higher
population densities.
CONCLUSIONS: Underlying comorbidity is associated with diagnostic delay amongst patients with DLBCL or FL. Results suggest a
possible correlation between CCGs with higher population densities and diagnostic delay of aggressive lymphomas.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01523-6
INTRODUCTION
Non-Hodgkin lymphoma is a heterogeneous disease comprising
over 60 morphological entities with diverse histological patterns
[1]. The most common of which are diffuse large B-cell (DLBCL)
and follicular lymphomas (FL), exhibiting an annual rate of 8.2 and
3.3 cases (respectively) per 100,000 people in the UK. These
subtypes are relatively common in adults, with incidence
increasing amongst older ages [2]. Each of these subtypes has
markedly differing treatments and health outcomes [1].
Survival of DLBCL or FL patients in England has steadily
increased over the past decades [3, 4], yet the proportion of
patients surviving trails that of other European countries [5].
Evidence has highlighted that diagnostic delay (compared to an
earlier diagnosis) is associated with a less intensive treatment plan,
which then impacts on the chances of survival [6]. Public health
policies have aimed to increase awareness, encourage more
patient and healthcare system interactions and set targets for
earlier cancer diagnosis [7–10].
In the UK, the cancer diagnostic route is defined as the first of
eight possible points of contact between the patient and the
healthcare system [11]. Emergency diagnosis is defined as a
diagnosis of cancer following presentation to an accident and
emergency unit, or following an emergency pathway for in/out-
patients: it is used as an indicator of diagnostic delay for cancer
patients [12]. Underlying comorbidities are known to affect the
timely diagnosis of other cancers [13–15]. Comorbidity expressing
symptoms similar to cancer may delay the diagnosis: dissimilar
symptoms may hasten the cancer diagnosis. For example,
some symptoms are present in both lymphomas and other
chronic diseases, such as swollen abdomen and fatigue in
diabetes [16], chest pain in congestive heart failure [17] and
shortness of breath in chronic obstructive pulmonary disease [18].
Furthermore, all three of these diseases are prevalent amongst
patients with lymphoma, which could explain misdiagnosis and
diagnostic delay [19, 20].
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A universal healthcare system (UHS), such as the National
Health Service (NHS) in England, aims to provide all residents with
access to healthcare [21]. However, variability in health outcomes
amongst patients with the same lymphoma still occurs [22, 23].
Clinical Commissioning Groups (CCGs) commission the hospital
and community NHS services, and decide on local priorities
(informed by general practices), for their respective geographical
areas; however, CCGs have shown variability in health outcomes
since their inception [24, 25], which may partly explain differences
in diagnostic delay.
We aim to assess the association between pre-diagnosed
comorbidities and diagnostic delay (i.e., route to diagnosis)
amongst patients with DLBCL or FL, accounting for patient
sociodemographic characteristics.
METHODS
Study design, participants, data and setting
We developed a population-based cross-sectional study comprising all
patients, aged 18 to 99 years, diagnosed with non-Hodgkin lymphoma
(NHL) between January 1, 2005 and December 31, 2013. NHL was coded
(C82.0-C85.9) according to the 10th revision of the International Statistical
Classification of Diseases and Related Problems (ICD) [26]. Morphology (cell
type) and topography (tumour site) were defined using renewed updates
of the ICD for Oncology (ICD-O); ICD-O-3 [27] was used for diagnoses up to
2010, and ICD-O-3.1 [28] for diagnoses after 2011. Patients diagnosed with
either DLBCL or FL were included in the study and are hereby referred to as
subtype (Supplementary Table S1) [26].
Information on patients’ cancer diagnosis was collected by the national
cancer registry and analysis service (NCRAS) [29]. The NCRAS contains England
national cancer registry data and Hospital Episode Statistics [30] (HES)
datasets that are accessed via the Cancer Analysis System [31] (CAS). Cancer
registry (CAS dataset) contained information on subtype (morphology), age at
diagnosis, ethnicity, gender and date of diagnosis. This was linked to HES,
which contained information on patient’s previous hospital admissions,
accident and emergency presentations, outpatient appointments.
Variables
Route to diagnosis, obtained from NCRAS, was originally recorded as one of
eight routes to diagnosis [11]. Patients with a ‘death certificate only’ route
to diagnosis were excluded to remove bias. There is no nationally
recognised screening programme for NHL, and no patients were
diagnosed via a ‘screen-detected’ route. An ‘unknown’ route to diagnosis
was recoded as a missing record. The remaining routes were dichotomised
into a binary variable indicating whether the patient was diagnosed
following an emergency or elective presentation: elective presentation
consisted of patients diagnosed through 2-week-wait, general practitioner
referral, inpatient elective and other outpatient.
Comorbidity status, based on the Charlson comorbidity index [32] (CCI),
was defined as “the existence of disorders, in addition to a primary disease
of interest, which are causally unrelated to the primary disease” [33, 34].
Comorbidities were coded within HES according to the International
Classification of Diseases, 10th revision (Supplementary Table S2). Previous
records of comorbidity were obtained from HES data. Patients with any
previous malignancy were removed. For each patient, we defined a time
window of 6–24 months prior to cancer diagnosis for a comorbidity to be
recorded. A patient’s CCI was determined using an algorithm developed by
Maringe et al. [35]. CCI was classified according to the Royal College of
Surgeons (RCS) Charlson Score [36], which was categorised into three
groups: 0 for no previous comorbidity, 1 for single comorbidity and 2 or
more for multimorbidity. We tabulated the prevalence of comorbidity for
DLBCL and FL (Supplementary Table S3).
Stage at diagnosis is based on the Ann Arbor classification system (CAS
dataset) [37]. A lower tumour stage is predictive of a higher survival
outcome compared to a higher tumour burden. For NHL subtypes, stages
I/II is a criterion for treatment of low tumour stage; stages III/IV is a criterion
for treatment of high tumour stage [38]. Therefore, early-stage was
dichotomised as I/II, and late-stage as III/IV.
Deprivation level (HES dataset) is based on the Lower Super Output Area
[39] (LSOA) of residence of the patient at the date of cancer diagnosis. An
LSOA is a geographical location with a median of 1500 inhabitants. From
the Index of Multiple Deprivation [40] (IMD), the income domain was
classified into one of five quintiles based on the national distribution of
ranked deprivation scores in the 32,844 LSOAs. Each patient was linked
with one of the 209 Clinical Commissioning Groups (CCG) where their
LSOA resides [41]. Lastly, ethnicity (HES dataset) was recorded as either
white or other.
Statistical analysis
We described the study population, tabulated the patient characteristics
with diagnostic delay markers (route to diagnosis), and calculated
unadjusted odds ratios (and 95% confidence intervals [CI]) with Wald test
P values.
We conducted analysis for DLBCL and FL separately. Univariable
independent logistic regression models were used to explore the crude
association between the route to diagnosis and each of the patient
characteristics. Then, multivariable generalised linear mixed-effect models
(GLMM) were used to account for the dependency between patients j= 1,
…,ni from CCG i= 1,…,209. The GLMM model for the route to diagnosis
was defined as
logit πij
  ¼ β0 þ bi þ β1Aij þ β2Gij þ β3Eij þ
X5
k¼2




where bi  Nð0; σ2bÞ. The patient, and tumour, characteristics were age (A),
gender (G), ethnicity (E), deprivation (D) and comorbidity score (C).
The model was estimated using maximum likelihood. Likelihood-ratio
tests were used to compare between models with and without each
covariate and for linear trend. Note that these and subsequent estimates
are for any given CCG as results from logistic mixed-effects models have
cluster-specific interpretation [42–45]. Empirical Bayes estimates of the
random effect bbi were used to explore the between-CCG variability in the
odds of the emergency route to diagnosis. The random-effect variance
parameter was tested for using a mixture of Chi-squares with 0 and 1
degrees of freedom [42, 43]. The mixture of the Chi-square test is a
likelihood-ratio-type test, where an appropriate reference distribution is
used to account for the fact that the null hypothesis in this case is at the
boundary of the parameter space [42, 46]. Combining likelihood-ratio tests
after multiple imputation requires derivation of a particularly modified
likelihood-ratio test statistic, which is compared with a particularly derived
reference distribution. For tests of fixed-effect parameters, the relevant
methodology exists [47]. We are not aware of the existing corresponding
methodology for combining after multiple imputation likelihood-ratio-type
tests for random-effect variance parameters.
Missing data analysis
Variables with missing data were the outcome (route to diagnosis [DLBCL:
1.9%, FL: 2.1%]), and ethnicity [DLBCL: 22.8%, FL: 24.9%]. Using logistic
regression models, we explored the missing data mechanism for each
partially observed variable. The imputation model included all fully- and
partially observed covariates and the cluster variable indicator. To reduce
potential bias [47], the auxiliary variables (patient’s vital status,
Nelson–Aalen estimate of the cumulative mortality hazard, and stage at
diagnosis) were included as, per the missing data indicator model, they
were predictive of the chance of missing values and, as per subject matter
knowledge, associated with the underlying values themselves [48]. We
used the latent normal joint modelling multiple imputation approach,
under a missing at random assumption, and generated ten imputed
datasets. The multilevel logistic regression models for each outcome were
fitted to each of these datasets and results combined using Rubin’s rules
[49, 50].
We used R software for all analysis; the glmer function of the lme4
package was used for generalised linear mixed-effects models, and the




In this study, we included 45,629 patients diagnosed with DLBCL
(30,078; 65.9%) or FL (15,551; 34.1%) between January 1, 2005 and
December 31, 2013 (Table 1A, B). The prevalence of emergency
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Table 1. (A) Summary statistics of the emergency route to diagnosis amongst patients diagnosed with diffuse large B-cell lymphoma (n= 30,078) in
England during 2005–2013; (B) summary statistics of the emergency route to diagnosis amongst patients diagnosed with follicular lymphoma (n=
15,551) in England during 2005–2013.







Age (mean, s.d.) 67.2 (14.8) 68.2 (15.5) 1.04c 1.03–1.06 <0.001
Gender
Male 10,658 (53.7) 5292 (54.7) Ref Ref Ref
Female 9175 (46.3) 4391 (45.4) 0.96 0.92–1.01 0.139
Ethnicity
White 14,583 (94.8) 6,898 (92.6) Ref Ref Ref
Minorities 802 (5.2) 549 (7.4) 1.44 1.29–1.62 <0.001
Missingd 4448 (22.4) 2236 (23.1) – – –
Deprivation
Least deprived 4410 (22.2) 1823 (18.8) Ref Ref Ref
2 4455 (22.5) 2105 (21.7) 1.14 1.06–1.23 <0.001
3 4145 (20.9) 2031 (21.0) 1.19 1.10–1.28 <0.001
4 3806 (19.2) 1993 (20.6) 1.27 1.17–1.37 <0.001
Most deprived 3017 (15.2) 1731 (17.9) 1.39 1.28–1.50 <0.001
Comorbidity
None 17,957 (90.5) 8396 (86.7) Ref Ref Ref
One 970 (4.9) 590 (6.1) 1.30 1.17–1.45 <0.001
Multimorbidity 906 (4.6) 697 (7.2) 1.65 1.49–1.82 <0.001







Age (mean, s.d.) 63.5 (13.5) 66.3 (14.2) 1.17c 1.13–1.21 <0.001
Gender
Male 6209 (46.5) 962 (51.2) Ref Ref Ref
Female 7144 (53.5) 917 (48.8) 0.83 0.75–0.91 <0.001
Ethnicity
White 9459 (94.9) 1399 (94.8) Ref Ref Ref
Minorities 510 (5.1) 77 (5.2) 1.02 0.80–1.31 0.870
Missingd 3384 (25.3) 403 (21.5) – – –
Deprivation
Least deprived 3100 (23.2) 375 (20.0) Ref Ref Ref
2 3040 (22.8) 405 (21.6) 1.10 0.95–1.28 0.205
3 2857 (21.4) 375 (20.0) 1.09 0.93–1.26 0.292
4 2462 (18.4) 412 (21.9) 1.38 1.19–1.61 <0.001
Most deprived 1894 (14.2) 312 (16.6) 1.36 1.16–1.60 <0.001
Comorbidity
None 12,410 (92.9) 1667 (88.7) Ref Ref Ref
One 536 (4.0) 95 (5.1) 1.32 1.05–1.65 0.015
Multimorbidity 407 (3.1) 117 (6.2) 2.14 1.73–2.65 <0.001
cOR crude odds ratio, CI confidence interval.
aIn all, 562 (1.9%) missing route to diagnosis records.
bCrude odds ratios for emergency vs elective.
cIncrease in odds of the emergency route for each 10-year increase in age.
d Proportions of missing records amongst all ethnicity records (including observed records).
eIn all, 319 (2.1%) missing route to diagnosis records.
Percentages may not sum to 100% due to rounding.
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diagnostic routes amongst those diagnosed with DLBCL or FL was
9683 (34.1%) and 1879 (12.3%), respectively, there was no
evidence of a yearly trend. Amongst these patients, the average
age at diagnosis was 68.2 and 66.3 years, respectively.
The prevalence of emergency diagnostic routes (compared to
elective) was higher amongst FL males, ethnic minorities in DLBCL,
and those living in the most deprived areas (both DLBCL and FL).
The emergency route, compared to elective, was more common
amongst those with multimorbidity: DLBCL (7.2% vs 4.6%,
respectively) and FL (6.2% vs 3.1%, respectively). Similarly, for
both DLBCL and FL, an increase in the crude odds of the
emergency route to diagnosis was strongly associated with an
increase in age and living in most deprived areas, while for an
ethnic minority it was observed in DLBCL only. There was an
increase in the odds of the emergency route to diagnosis with
each increase in deprivation level.
Multivariable mixed-effect logistic regression models
Table 2A, B shows the results from the multivariable GLMM for odds
of the emergency route to the diagnosis of DLBCL and FL,
respectively. For both DLBCL and FL, under complete case analysis,
we found that for any given CCG, the presence of comorbidity was
associated with the emergency route to diagnosis: the association
was largest amongst those with a comorbidity status of two or more
(Table 2A, B). Living in more deprived areas was strongly associated
with the emergency route to diagnosis.
After multiple imputation (Table 2A, B), there were similar
conclusions to the complete case analysis. Amongst patients from
the same CCG, having a comorbidity score of 2 or more, compared
to no comorbidity, was strongly associated with an emergency
route to diagnosis (DLBCL: OR 1.56, CI 1.40–1.73; FL: OR 1.80, CI
1.45–2.23). There was weak evidence of a trend for deprivation
and comorbidity index amongst DLBCL (P= 0.054 and P= 0.060,
respectively); however, there was no evidence of a trend amongst
FL (P= 0.206 and P= 0.113, respectively).
Using a mixture of Chi-square tests with 0 and 1 degree of
freedom (i.e. half the P value from a Chi-square with 1 degree of
freedom), we found strong evidence of between-CCG variability in
the odds of the emergency route to diagnosis (DLBCL: P < 0.005;
FL: P < 0.001). The variance of the CCG random effects of the
models for DLBCL and FL indicated some heterogeneity between
CCGs in routes to diagnosis.
We graphically illustrate, from our analysis accounting for both
clustering and missing data, the Empirical Bayes (EB) estimates of
the CCG random effects for odds of the emergency route to
diagnosis (Figs. 1 and 2). These are used to explore the between-
CCG variability. A positive EB estimate indicated a higher
probability of emergency route to diagnosis for a patient from
that CCG in comparison to a patient who has similar observed
characteristics but from a CCG with either a less positive, or a
negative EB estimate. For DLBCL, there are possibly a few outlying
CCGs with the lowest probabilities, and possibly an outlying one
with the highest probability. For FL, there are possibly a few
outlying ones with the highest probabilities. To explore possible
patterns, the size of the markers were weighted by the population
density for the respective CCG and have a lighter shade for a
higher proportion of missing records of the route to diagnosis.
For DLBCL (Fig. 1), the results show a slight pattern such that
there were more CCGs with a larger population density (larger-
sized markers) that had a higher probability for their patients
being diagnosed through an emergency route to diagnosis
(markers with EB estimates above 0). There was no apparent
pattern for patients with FL (Fig. 2).
DISCUSSION
We aimed to assess the association between comorbidity status
and a marker of diagnostic delay (route to diagnosis), amongst
patients diagnosed with non-Hodgkin lymphoma, adjusting for
patient and healthcare pathway characteristics.
We found that comorbidity status was significantly associated
with the emergency route to diagnosis, after adjusting for age,
gender, ethnicity and deprivation and accounting for clustering
due to CCG did not explain the relative difference. The more severe
the comorbidity score, and those living in more deprived areas,
increased the odds of the emergency route to diagnosis. Our
results are consistent with previous findings of an increase in the
probability of emergency route to diagnosis [6, 52], and, in other
countries and for other cancers, comorbidities were associated
with diagnostic delay [53]. Similar results were found amongst
studies investigating colon cancer [54, 55]. Since the proportion of
patients with emergency route remains stable over calendar time,
this phenomenon is not thought to be time-dependent.
Deprivation level was a strong independent predictor of the
route to diagnosis after adjusting for comorbidity and other
factors (Table 2A, B); however, accounting for clustering increased
the strength of the association for patients living in more deprived
areas. This suggests that the difference in diagnostic delays
between deprivation groups is partly explained by unobserved,
and possibly unmeasured, characteristics of CCGs. A characteristic
of CCGs, not explored in this study but for other cancers, could be
accessed to the healthcare system (e.g., accessibility to a GP
appointment) [56]. Previous studies [57] have found delays in
diagnosis since first symptoms and suggested introducing rapid
access to lymph node diagnostic clinics [58] and providing: less
variability in the number of GP appointments attended before a
diagnosis [59, 60], clearer definitions of symptoms [61], and
appropriate patient-oriented information when previous investi-
gations rule out cancer [15]. These unmeasured characteristics of
CCGs could explain the large between-CCG variation in outcomes.
In the United States, and for other malignancies, physician supply
is associated with early detection of breast cancer [62], and higher
primary care physician density is associated with a lower incidence
of late-stage colorectal cancer [63].
Contrary to the assurances of a universal healthcare system,
such as the NHS, our results suggest inequitable access to
healthcare services between CCGs (i.e., more densely populated
CCGs appear to have patients with a greater chance of diagnostic
delay compared to less densely populated CCGs). Patients
diagnosed through the emergency route are patients that either
could not access a GP appointment or the GP appointment was
inconclusive: during this waiting time, cancer can progress and
the patient admitted themselves to the emergency department.
Inequalities may be due to a combination of competing demands
and a lack of clinical guidance regarding symptoms. However, lack
of clinical guidance would be a non-differential misclassification
and this would not explain the inequalities in the emergency route
amongst patient characteristics.
Our results challenge previous research that did not find
evidence of a difference in diagnostic delay between deprivation
levels using unadjusted analyses; although, previous studies were
based on a smaller sample size that were potentially under-
powered in comparison to our study [6]. We highlight that
deprivation is predictive of the diagnostic route if analyses do not
account for CCGs that widely differ, among other dimensions, in
healthcare provision [64]. Furthermore, the late lymphoma stage
at diagnosis seems associated with poorer survival. Evidence is
limited due to the extended use of the FL and DLBCL International
Prognostic Indices (FLIPI and IPI, respectively) and for lymphoma
prognosis and survival outcomes. The indices, in addition to the
lymphoma stage, integrate other prognostic factors such as serum
lactate dehydrogenase, the number of nodal site involvement,
patient ages, and haemoglobin. Evidence shows that a higher
index score, and thus a higher stage, is associated with poorer
health outcomes and survival: highlighting the necessity of
prompt management among patients at an advanced stage [65].
M.J. Smith et al.
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We graphically illustrated that patients living in CCGs with more
dense populations have a higher probability of emergency route
to diagnosis. To our knowledge, there is yet no research into the
relationship between population density and diagnostic delay of
cancer in England. This study shows that NHL patients living in
CCGs with higher population densities have a higher probability of
emergency route to diagnosis. On one hand, deprivation tends to
be correlated with high population density in England [66], and is
also associated with higher use of emergency services [67]. On the
other hand, population density is independently associated with
Table 2. (A) Multivariable GLMM for the odds of the emergency route to diagnosis in (a) complete case analysis, (b) multiple imputation amongst
patients (n= 30,078) diagnosed with diffuse large B-cell lymphoma in England during 2005–2013; (B) multivariable GLMM for the odds of the
emergency route to diagnosis in (a) complete case analysis, (b) multiple imputation amongst patients (n= 15,551) diagnosed with follicular
lymphoma in England during 2005–2013.
(A) (a) Complete case analysis (n= 22,832) (b) After multiple imputation (n= 30,078)
OR 95% CI P value OR 95% CI P value
Agea 1.03 1.02–1.04 0.002 1.05 1.04–1.06 <0.001
Gender
Male Ref Ref Ref Ref
Female 0.95 0.90–1.01 0.082 0.95 0.91–1.00 0.061
Ethnicity
White Ref Ref Ref Ref
Minority 1.44 1.28–1.62 <0.001 1.42 1.26–1.60 <0.001
Deprivation
Least deprived Ref Ref Ref Ref
2 1.14 1.04–1.24 0.003 1.13 1.05–1.22 0.001
3 1.18 1.08–1.29 <0.001 1.17 1.08–1.27 <0.001
4 1.23 1.12–1.34 <0.001 1.23 1.14–1.34 <0.001
Most deprived 1.24 1.13–1.36 <0.001 1.32 1.21–1.43 <0.001
Comorbidity
None Ref Ref Ref Ref
One 1.26 1.12–1.41 <0.001 1.27 1.14–1.41 <0.001
Multimorbidity 1.58 1.41–1.78 <0.001 1.56 1.40–1.73 <0.001





(B) (a) Complete case analysis (n= 11,445) (b) After multiple imputation (n= 15,551)
OR 95% CI P value OR 95% CI P value
Agea 1.15 1.12–1.17 <0.001 1.17 1.15–1.19 <0.001
Gender
Male Ref Ref Ref Ref
Female 0.76 0.68–0.85 <0.001 0.80 0.73–0.89 <0.001
Ethnicity
White Ref Ref Ref Ref
Minority 1.03 0.80–1.32 0.835 1.03 0.81–1.29 0.833
Deprivation
Least deprived Ref Ref Ref Ref
2 1.16 0.98–1.38 0.084 1.11 0.95–1.29 0.190
3 1.09 0.92–1.30 0.312 1.07 0.92–1.24 0.396
4 1.42 1.20–1.69 <0.001 1.38 1.18–1.61 <0.001
Most deprived 1.38 1.14–1.66 <0.001 1.39 1.18–1.64 <0.001
Comorbidity
None Ref Ref Ref Ref
One 1.18 0.92–1.51 0.190 1.19 0.94–1.49 0.143
Multimorbidity 1.78 1.40–2.26 <0.001 1.80 1.45–2.23 <0.001





OR odds ratio, CI confidence interval.
aIncrease in odds of emergency route to diagnosis for each 10-year increase in age at diagnosis.
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high emergency calls [68]. This could be because highly dense
areas accumulate high demands that are not completely covered
by available healthcare resources; accordingly, this demand could
be exacerbated by the association between deprivation and the
prevalence of comorbidities. This association has not been well
explored, but it is likely that cancers other than NHL are affected
by the association between the prevalence of emergency route to
diagnosis and population density. Further research should be
conducted to determine the need for greater availability of
healthcare services in more populated areas.
Furthermore, there will be differences in the availability and
specialisation of cancer-specific resources between CCGs. For
example, a CCG may have a specialised centre for breast cancer
but not for another cancer. Additional analyses are needed to
provide a full interpretation of these results. Densely populated areas
may be associated with populations from less favourable back-
grounds and potentially higher pressure on the healthcare system.
CCGs were established from the Health and Social Care Act 2012 and
replaced Primary Care Trusts (PCTs). However, CCGs and PCTs were
constructed based on administrative boundaries, and the population
size of CCGs are similar to the PCTs they replaced. Since 2013, the
number of CCGs have reduced due to mergers [69], and the
proportion of late-staged lymphomas has increased [70], possibly
indicating competition for healthcare services.
Our study is strengthened by the large population-based
sample capturing all patients with a diagnosis of DLBCL and FL
between 2005 and 2013. To date, this is the largest study of
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(B) Follicular lymphoma
Fig. 2 Variance of diagnostic delay of follicular lymphomas amongst clinincal commissioning groups. Empirical Bayes estimates of the
random effects from the model for the route to diagnosis, by each Clinical Commissioning Group amongst patients (n= 15,551) diagnosed
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(A) DLBCL
Fig. 1 Variance of diagnostic delay of diffuse large B-cell lymphoma amongst clinical commissioning groups. Empirical Bayes estimates of
the random effects from the model for the route to diagnosis, by each Clinical Commissioning Group, amongst patients (n= 30,078)
diagnosed with diffuse large B-cell lymphoma in England during 2005–2013.
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diagnosed according to the latest (ICD-O-3) well-defined WHO
cancer classifications, and through a linkage of databases we
obtained reliable information on comorbidity diagnosis prior to,
and likely independent of, cancer. The objective data sources
provide information on patients that is gathered prospectively,
preventing differential misclassification.
Despite the lack of well-defined guidance on which comorbidity
index is the gold standard depending on the setting of the study,
Charlson comorbidity index (CCI) is one of the most commonly
used comorbidity indices in population-based cancer epidemiol-
ogy [71]. We used the Royal College of Surgeons’ adaptation of the
CCI, which provides a cancer-specific comorbidity indicator, and is
advantageous in comparison to other indices that measure
underlying comorbidities as independent from each other
[32, 71, 72]. Computed algorithms were used to define comorbid-
ity status, which strengthens the reliability of this study [35].
In this study, we had missing data in two dimensions: route to
diagnosis (the outcome) and explanatory variables. Missing data in
outcomes present less complexity when using a likelihood-based
analysis such as a generalised linear mixed model, as the
ignorability property assures the validity of results from analysis
of the complete cases, under a missing at random mechanism
[42, 47]. With missing data additionally in explanatory variables,
analyses are more complex, as multiple imputation is in general
needed to achieve validity of results under a missing at random
mechanism, if the outcome is included in the missingness
mechanism for these variables. Research in missing data has
shown that multiple imputation has the potential to mitigate bias
and loss of efficiency; whether multiple imputation provides gains
over a complete case analysis cannot be simply determined from
the proportion of incomplete cases in a single variable. Indeed,
potential benefits from multiple imputation depend on factors
such as whether missing data occur in the explanatory variable of
interest or covariates, and interrelationships between the variables
[73]. Lee and Carlin [73] and White and Carlin [74] have
highlighted the importance of conducting both a complete case
analysis and an analysis after multiple imputation, and carefully
compare results. We used the latent normal joint modelling
multiple imputation approach under a missing at random
assumption to account for the missing ethnicity and route to
diagnosis. This approach allows imputation of a mix of variable
types, while accounting for multilevel structures arising from
clustering of patients [47, 75, 76]. As with all missing data
problems, it is impossible to distinguish between a missing at
random and a missing not at random mechanism based on the
observed data [47, 77–79]. Follow-up work will therefore involve
assessing the sensitivity of our results to departures from the
missing at random mechanism, by imputing under a missing, not
at random assumption.
A limitation of this study is that route to diagnosis does not
entirely encapsulate the patient’s multifaceted experiences along
the healthcare pathway prior to a cancer diagnosis. Information on
performance status and education were not available but may
have contributed to differences in diagnostic delay. Firstly, distinct
from having comorbidity, performance status measures the
patient’s ability to carry out everyday tasks, such as reaching the
healthcare system, which may contribute to diagnostic delay [6].
Secondly, the low average time allocated for each GP appoint-
ment requires the patient to use the English language efficiently
and describe important symptoms in a concise manner, which
may hasten the cancer diagnosis [80].
CONCLUSION
Patients with DLBCL or FL are more likely to experience an
emergency route to diagnosis if they have underlying comorbidity.
Differences in diagnostic delay indicators between deprivation
levels are minimally explained by comorbidity status, and are
further explained by differences in the healthcare provisions
between clinical commissioning groups (CCG). DLBCL patients
living in CCGs with higher population densities have a higher
probability of emergency route to diagnosis.
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